TY  - JOUR
AU  - López-Grueso, María José
AU  - González, Raúl
AU  - Muntané, Jordi
AU  - Bárcena, José Antonio
AU  - Padilla, C Alicia
PY  - 2019
DO  - 10.3390/antiox8100501
SN  - 2076-3921
UR  - https://hdl.handle.net/10668/26795
T2  - Antioxidants (Basel, Switzerland)
AB  - Sorafenib is the first-line recommended therapy for patients with advanced hepatocarcinoma (HCC) in de-differentiation stage (presenting epithelial-mesenchymal transition, EMT). We studied the role of the thioredoxin system (Trx1/TrxR1) in the...
LA  - en
KW  - EMT
KW  - hepatocarcinoma
KW  - redox signaling
KW  - sorafenib
KW  - thioredoxin
TI  - Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells.
TY  - research article
VL  - 8
ER  -